Wolfe Research Initiates Coverage on Kestra Medical Technologies (NASDAQ:KMTS)

Stock analysts at Wolfe Research started coverage on shares of Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) in a research note issued on Monday, Marketbeat Ratings reports. The brokerage set an "outperform" rating and a $29.00 price target on the stock. Wolfe Research's price objective would indicate a potential upside of 24.52% from the stock's current price.

Several other analysts have also recently issued reports on KMTS. The Goldman Sachs Group began coverage on Kestra Medical Technologies in a research report on Monday. They set a "neutral" rating and a $24.00 target price on the stock. Wells Fargo & Company began coverage on Kestra Medical Technologies in a research report on Monday. They set an "overweight" rating and a $28.00 price objective on the stock. Stifel Nicolaus assumed coverage on shares of Kestra Medical Technologies in a report on Monday. They issued a "buy" rating and a $28.00 target price for the company. Finally, Piper Sandler initiated coverage on shares of Kestra Medical Technologies in a research report on Monday. They issued an "overweight" rating and a $27.00 price objective on the stock. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $27.67.

Kestra Medical Technologies Price Performance

NASDAQ KMTS traded down $0.73 during trading on Monday, reaching $23.29. 62,011 shares of the company's stock traded hands, compared to its average volume of 275,704. Kestra Medical Technologies has a 12-month low of $20.00 and a 12-month high of $26.06.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.